Dicerna Pharmaceuticals, Inc., a Watertown, Mass.-based biopharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, raised $60m in Series C financing.
The round was led by new investor RA Capital with participation from Brookside Capital, Deerfield, and Omega Funds and existing institutional investors Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One. In conjunction with the funding, RA Capital’s partner Peter Kolchinsky, Ph.D., has joined Dicerna’s board of directors.
Led by Douglas M. Fambrough, Ph.D., chief executive officer, Dicerna uses its Dicer Substrate Technology™ platform and EnCore™ delivery technology to develop a pipeline of programs to reach intracellular disease targets.
The company intends to use the funds to advance two or more programs into the clinic and to progress other preclinical programs. It also plans to continue to develop innovative drug delivery systems, which combine its DsiRNA molecules with targeting moieties allowing for direct delivery into specific cells of interest.
21/10/2010: DICERNA PHARMACEUTICALS SECURES ADDITIONAL $4M IN SERIES B FINANCING
11/08/2010: DICERNA PHARMACEUTICALS CLOSES $25M SERIES B ROUND OF FINANCING